Background This study was performed to assess the initial results and long-term follow-up of Morrow septal myectomy for patients with hypertrophic obstructive cardiomyopathy
. There were no perioperative deaths, and the postoperative course was uneventful for all except 2 of the patients. One patient required implantation of a pacemaker due to a complete heart block, and in 1 patient a small ventricular septal defect was caused. Follow-up (mean, 6.8 years) was 100% complete. No patient was reoperated for recurrent HOCM. All except 1 patient experienced a major functional improvement with a decrease of the mean New York Heart Association functional class from 3.0 before operation to 1.5 at follow-up (P<.001). Symptoms persisting during follow-up were angina pectoris in 3 of 22 patients (14%), dyspnea in 6 of 30 patients (20%), dizzy spells in 2 of 12 patients (17%), and syncope in 2 of 10 patients (20%). During follow-up no HOCM related death occurred. All The perioperative course was not complicated by any deaths. The postoperative course was uneventful except for a complete heart block in 1 patient who required placement of a permanent pacemaker and a small ventricular septal defect in another patient, who is still asymptomatic.
The long-term follow-up was 100% complete, and all of the patients were restudied clinically and by Doppler echocardiography. The mean follow-up period was 6.8 years (range, 0.5 to 14 years). During this follow-up, none of the patients were reoperated for recurrent HOCM, and there was a significant decrease in symptomatology. The mean NYHA functional class decreased from 3.0±0.6 before surgery to 1.5±0.6 (P<.001) at the time of follow-up (Fig 1) There was a decrease in mitral regurgitation after operation with a mean decrease of 0.5 grade (95% confidence limits, -0.873 to -0.0466; P=.03). Almost 50% of the patients had no mitral regurgitation, and the other 20 patients had trivial to moderate mitral regurgitation. There was no severe mitral regurgitation during follow-up (Fig 2) . As is shown in Fig 3, Why the long-term follow-up results of this study are this good cannot be fully explained. In the literature, a postoperative annual mortality rate of 2.2% to 4.4% has been reported.5 Selection of a lower-risk group does not appear to be the reason in this study, since the mean NYHA functional class was 3.0±0.6. Furthermore, medical therapy had eventually failed in all of these patients. In our view, the main explanation is that one surgeon performed the surgery on all of the study patients. Whether septal myectomy actually decreases long-term mortality remains unknown. To compare the patients who have had a septal myectomy with those who are being treated medically is of dubious validity, since the operated patients constitute a different subgroup than the nonoperated patients. Nevertheless, the fact that the annual mortality rate in this study is so much lower than that for patients who are treated medically suggests a more favorable course after surgery.5 This is especially true if one takes into consideration that the operated patients usually are the most severely symptomatic patients, as was the case in our study.
During long-term follow-up, the HOCM-related event rate was very low: only 1 patient had a syncope due to a complete atrioventricular block that required a pacemaker and another patient had a late sustained ventricular tachycardia that was successfully treated with amiodarone.
Mitral regurgitation in HOCM is a functional phenomenon that regresses after adequate septal myectomy as was also noted in our study, even study shows that transsection of the conduction pathways can be avoided by paying careful attention to the anatomic structures, only one patient (3%) in our study needed a permanent pacemaker after septal myectomy. Third, the reduction of the left ventricular outflow tract gradient to 6±4 mm Hg in this study is far better when compared with the mean rest gradient of 40 mm Hg after dual-chamber pacing.10"1 Last, in our study only one hemodynamically insignificant ventricular septal defect was caused. Fananapazir et al10"'1 conclude that dual-chamber pacing should be tried in all patients with HOCM in whom symptoms are refractory to medical therapy. However, their conclusions appear to be premature. Even though their short-term follow-up results are promising, the follow-up of pacing studies is still too short (1.5 to 14 months) to make any definite conclusions. The effect of a high rest gradient with dualchamber pacing on left ventricular function must to be awaited. A rest gradient of 215 mm Hg has been shown to be an independent predictor of mortality after myectomy. 21 In conclusion, on the basis of the results of this study, we believe that transaortic septal myectomy is still the treatment of choice for patients with HOCM with a significant gradient in the left ventricular outflow tract and symptoms refractory to medical therapy. It is a very safe and effective procedure with an excellent long-term clinical and echocardiographic follow-up. Although the initial results of dual-chamber pacing seem promising, prospective studies are needed to compare Morrow septal myectomy with dual-chamber pacemaker therapy to evaluate the most effective form of therapy.
